Human PCSK9 Protein
- Known as:
- Human PCSK9 Protein
- Catalog number:
- PC9-H5223
- Product Quantity:
- 1mg
- Category:
- -
- Supplier:
- acrobyosystems
- Gene target:
- Human PCSK9 Protein
Related genes to: Human PCSK9 Protein
- Gene:
- PCSK9 NIH gene
- Name:
- proprotein convertase subtilisin/kexin type 9
- Previous symbol:
- HCHOLA3
- Synonyms:
- NARC-1, FH3
- Chromosome:
- 1p32.3
- Locus Type:
- gene with protein product
- Date approved:
- 2003-05-13
- Date modifiied:
- 2019-04-23
Related products to: Human PCSK9 Protein
Related articles to: Human PCSK9 Protein
- PCSK9 inhibitors (PCSK9i) are at the center of research for their pleiotropic effects. The aim of this study is to systematically review the literature for their effect on vascular endothelial dysfunction. - Source: PubMed
Publication date: 2026/05/06
Antza ChristinaAnyfanti PanagiotaSavva CharalampiaMalandris KonstantinosBelančić AndrejŞener Yusuf ZiyaChaida EvangeliaPoulis DimitriosKotsis Vasilios - Acute ischemic stroke (AIS) triggers a complex systemic immune-inflammatory response. While proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors provide significant lipid-lowering and pleiotropic anti-inflammatory effects, their impact on early peripheral inflammatory and immune responses in AIS patients due to large artery atherosclerosis (LAA) remains underexplored. - Source: PubMed
Publication date: 2026/04/30
Li ZhenzhenSun CongZhang QingJi LifanZhang YitingLi ShuoGu MengmengGao JieHuang ZhihuiWang MengZhou JunshanZhu LinJiang TengZhou QingDeng Qiwen - Given the high costs of treatment with proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) and the limited US Food and Drug Administration label for these treatments in patients with stroke due to atherosclerotic disease, it is unknown whether these agents are cost-effective for reducing recurrent stroke events. - Source: PubMed
Publication date: 2026/05/01
Kellogg CarolineBadillo Goicoechea ElenaKim David DYaghi ShadiChaturvedi SeemantMehendale RachelOrjuela KarenKass-Hout TareqMorsi Rami ZMorales JacquelineSingh EeshaJhaveri AdityaPrabhakaran ShyamSmith Matthew MBrorson James RGolani SamikshaMazuera SofiaKang RachaelEltatawy AliPillajo JessicaSiegler James E - Statin therapy up-titration is hindered in heart-transplant (HT) recipients due to concern for pharmacological interactions and side effects. Alternative lipid lowering therapies (LLT) are now available for patients who are poorly tolerant to statins or those with significant dyslipidaemia despite maximal dose statin treatment and dietary advice. Real-world studies with non-statin LLT are limited in HT population. - Source: PubMed
Publication date: 2026/05/05
Bacich DanielaItaliano Enrico GiuseppeFaggioli MarikaRizzo LauraPradegan NicolaToscano GiuseppeTessari ChiaraTarzia Vincenzo - Familial hypercholesterolaemia (FH) is an inherited lipid disorder characterized by elevated low-density lipoprotein cholesterol (LDL-C) levels and increased risk of atherosclerotic cardiovascular disease. Despite its high prevalence, FH remains underdiagnosed and undertreated in many regions, particularly in low- and middle-income countries. - Source: PubMed
Publication date: 2026/04/15
Sahoo Saroj KumarSingh Prabhat KumarBarik RamachandraPrakash SatyaSahoo DebanandaMohanty Chitta RanjanMalla Sindhu RaoMohapatra Rakesh Kumar